Analgesics in France

October 2019 | 4 pages | ID: A446B9D1B01EN
Euromonitor International Ltd

Abstracts

Following another sharp drop in analgesics sales in current value terms in 2018, the category performance continued to be negative in 2019, albeit with sales falling at a slower rate than a year earlier. The repercussions from the ban on OTC sales of codeine-based combination products continue to be seen, although the main collapse in sales of combination products - analgesics had already been seen prior to 2019. Some adult combination products can still be sold without prescription, such as Act...

Euromonitor International's Analgesics in France report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2014-2018, allowing you to identify the sectors driving growth. Forecasts to 2023 illustrate how the market is set to change.

Product coverage: OTC.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?

• Get a detailed picture of the Analgesics market;
• Pinpoint growth sectors and identify factors driving change;
• Understand the competitive environment, the market’s major players and leading brands;
• Use five-year forecasts to assess how the market is predicted to develop.

Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.

Contents

HEADLINES
PROSPECTS
Analgesics suffers from a weak flu season, the codeine-based combination products ban and ibuprofen’s struggles
Bad press means ibuprofen sales continue to decline
Acetaminophen most dynamic as it benefits from the woes of the other analgesic types
COMPETITIVE LANDSCAPE
Doliprane helps Sanofi to continue gaining share
Laboratoires UPSA’s share slips as it gets a new owner in Taisho Pharmaceutical Holdings
Uncertain times for topical analgesics/anaesthetic
CATEGORY DATA
Table 1 Sales of Analgesics by Category: Value 2014-2019
Table 2 Sales of Analgesics by Category: % Value Growth 2014-2019
Table 3 NBO Company Shares of Analgesics: % Value 2015-2019
Table 4 LBN Brand Shares of Analgesics: % Value 2016-2019
Table 5 Forecast Sales of Analgesics by Category: Value 2019-2024
Table 6 Forecast Sales of Analgesics by Category: % Value Growth 2019-2024
EXECUTIVE SUMMARY
Consumer health continues to grow despite declining self-medication levels
Reverse switches and trend towards more natural products
Sanofi continues to lead
Chemists/pharmacies continues to dominate distribution
Continued current value growth expected over the forecast period
MARKET INDICATORS
Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2014-2019
Table 8 Life Expectancy at Birth 2014-2019
MARKET DATA
Table 9 Sales of Consumer Health by Category: Value 2014-2019
Table 10 Sales of Consumer Health by Category: % Value Growth 2014-2019
Table 11 NBO Company Shares of Consumer Health: % Value 2015-2019
Table 12 LBN Brand Shares of Consumer Health: % Value 2016-2019
Table 13 Penetration of Private Label in Consumer Health by Category: % Value 2014-2019
Table 14 Distribution of Consumer Health by Format: % Value 2014-2019
Table 15 Distribution of Consumer Health by Format and Category: % Value 2019
Table 16 Forecast Sales of Consumer Health by Category: Value 2019-2024
Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2019-2024
APPENDIX
OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
Switches
Summary 1 OTC: Switches 2018-2019
DEFINITIONS
SOURCES
Summary 2 Research Sources